TABLE 2.

Summary of published meta-analyses on NMDAR-targeted drugs.

Year	Drugs	Negative symptoms	Cognitive dysfunction
2010	glycine, D-serine, DCS, sarcosine	SMD = 0.38, 95% CI = 0.19 to 0.56, p < 0.0001	SMD = 0.28, 95%CI = 0.10 to 0.47, p = 0.002
2011	glycine, D-serine, DCS, sarcosine, NAC,	SMD = -0.27, 95% CI = -0.49 to -0.05, p = 0.01
2013	DCS, D-serine	SMD = 0.62, 95% CI = 0.34 to 0.90, p < 0.0001	SMD = 0.06, 95%CI = -0.22 to 0.35, p = 0.661
2015	D-serine, DCS, benzoate, NAC		SMD = 0.08, 95%CI = -0.06 to 0.23, p = 0.57
2019	D-serine, DCS, benzoate and NAC		SMD = 0.068, 95%CI = -0.056 to 0.193, p = 0.283